A Phase 1/2 interventional study of Umbilical cord mesenchymal stem cells in Autism, sponsored by Translational Biosciences. Completed at 1 site in Panama. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2017-10-13.
Sponsored by Translational Biosciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Allogeneic (not from the subject) human umbilical cord tissue-derived stem cells administered intravenously (IV) in a series of 4 infusions every 3 months over the course of one year is safe and will induce a therapeutic effect in autism patients.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
This study's enrollment of 20 is below the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Browse Autistic Disorder studies →Translational Biosciences is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Umbilical cord mesenchymal stem cells
Number of participants with adverse events
Time frame: 89 weeks
Number of participants with a change in disability as measured by the Autism Treatment Evaluation Checklist (ATEC)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
Number of participants with a change in disability as measured by the Childhood Autism Rating Scale (CARS)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
Change from baseline macrophage-derived chemokine (MDC)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
Change from baseline thymus and activation-regulated chemokine (TARC)
Time frame: 13 weeks, 25 weeks, 37 weeks, 49 weeks, 89 weeks
The record gives a start of Jul 2014, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solizmestrocel
Translational Biosciences